Pharma giant Novo Nordisk, which makes the obesity drug Wegovy, says the widespread availability of copycat medications is hurting its sales.

Are we truly on the brink of a cure for obesity? Or could neglecting the root causes risk worsening the very problems we seek ...

Pharma giant Novo Nordisk, which makes the obesity drug Wegovy, says the widespread availability of copycat medications is hurting its sales.

Bank of America analysts on Friday said Novo Nordisk may miss first-quarter expectations, as sales of its blockbuster Wegovy ...

A woman who has endured comments about her weight since she was five lost 3st in three months after taking weight loss drug ...

The proposed UK assisted dying law may be delayed until 2029, raising doubts about its future. Novo Nordisk's shares tumble ...

Novo Nordisk’s (NVO) stock has dropped by 25% in March (on the Copenhagen exchange) to put it on track for its biggest ...

LONDON (Reuters) -Novo Nordisk shares have fallen 25% so far in March and are on track for their biggest monthly drop since ...

Ozempic can lead to weight loss; however, intuitive eating advocates believe listening to your body’s hunger signals garner ...

Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors’ perception of the ...

Novo Nordisk NVO announced an update to the savings offer for its popular obesity injection, Wegovy (semaglutide). This ...